Symbol="SABSW"
AssetType="Common Stock"
Name="SAB Biotherapeutics Inc"
Description="SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts."
CIK="1833214"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2100 EAST 54TH STREET NORTH, SIOUX FALLS, SD, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="None"
EBITDA="17225900"
PERatio="0.486"
PEGRatio="None"
BookValue="1.086"
DividendPerShare="None"
DividendYield="0"
EPS="0.292"
RevenuePerShareTTM="2.225"
ProfitMargin="0.215"
OperatingMarginTTM="0.21"
ReturnOnAssetsTTM="0"
ReturnOnEquityTTM="0"
RevenueTTM="78361000"
GrossProfitTTM="0"
DilutedEPSTTM="0.292"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.925"
AnalystTargetPrice="None"
TrailingPE="0.486"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="-"
EVToRevenue="-"
EVToEBITDA="-"
Beta="None"
num_52WeekHigh="0.225"
num_52WeekLow="0.0275"
num_50DayMovingAverage="0"
num_200DayMovingAverage="0"
SharesOutstanding="0"
DividendDate="None"
ExDividendDate="None"
symbol="SABSW"
open="0.11"
high="0.14"
low="0.10"
price="0.14"
volume="15965.00"
latest_trading_day="2023-07-07"
previous_close="0.11"
change="0.03"
change_percent="29.0909%"
aroon_positive_momentum_days="85"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="85"
Volume_recent_avg="19656"
Change_recent_avg="0.01"
Delta_recent_avg="0.02"
Variance_recent_avg="0.01"
Change_ratio_recent_avg="-1.69"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="85"
Aroon_momentum_negative="15"
image_negative_thumbnail_id_1="102"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0074.jpeg"
image_negative_thumbnail_id_2="1164"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0198.jpeg"
image_neutral_thumbnail_id_1="555"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0044.jpeg"
image_neutral_thumbnail_id_2="432"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="1015"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0177.jpeg"
image_positive_thumbnail_id_2="957"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0119.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
